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Summary. Background: Inflammatory reactions contribute to
the development of arterial disease. We investigated the role of
interleukin-4 (IL-4) in thedevelopmentofmyocardial infarction
(MI) by genotyping patients with MI and control subjects for
the )589C>T (rs2243250) single nucleotide polymorphism
(SNP), which tags a functional haplotype of IL-4.Methods and
results: Study of Myocardial Infarctions Leiden (SMILE)
included 560 men with a first MI and 646 control subjects. The
Valencia study included 305 patientswithMI at£52 years (men
and women) and 310 control subjects. In SMILE no clear
overall association with the )589C>T genotype was found
[odds ratio (OR) 0.84; 95%CI 0.37–1.95 for )589TT and 0.82;
95% CI 0.62–1.07 for )589CT compared with )589CC]. In
patients younger than 50 years, carriership of one or two)589T
alleles was associated with a reduced risk ofMI (OR 0.57: 95%
CI 0.34–0.95). This result was replicated in the Valencia study,
where carriers of one or two)589T alleles had a reduced risk of
MI (OR0.67: 95%CI 0.47–0.95), with a strong protective effect
of the )598T allele in homozygous )589T (OR 0.33: 95% CI
0.10–1.05). In the control subjects of the Valencia study, the
)589T allele was associated with reduced levels of F1+2.
Conclusion:Ourdata indicate that the IL-4haplotype tagged by
the )589T allele reduces the risk of MI in young individuals.
Keywords: atherosclerosis, genes, inflammation, interleukin-4,
myocardial infarction.
Introduction
Myocardial infarction (MI) is the result of atherosclerosis
followed by plaque rupture or erosion and thrombosis; these
pathological conditions can be triggered and enhanced by
inflammation [1]. Interleukin-4 (IL-4) is a pleiotropic cytokine
produced by Th2-cells, eosinophils and mast cells. It mediates
the humoral immune response and exerts anti-inflammatory
effects by inhibiting the production of pro-inflammatory
cytokines and by changing the expression profile of macro-
phages [2]. The role of IL-4 in the development and progression
of complex diseases has been studied using single nucleotide
polymorphisms (SNPs) in the IL-4 gene (IL-4) which are
associated with IL-4 expression. The rare alleles of these
polymorphisms were found to be associated with high IL-4
expression [3], elevated total serum IgE [4–6], increased severity
and progression of asthma [3,7], IgA nephropathy [8], certain
carcinomas [9,10], late onset disease in AIDS (however, not in
all studies) [11–13] and Th1-type diseases, such as multiple
sclerosis [14,15] and rheumatoid arthritis [16,17].
In IL-4 several SNPs have been identified [3–5,18]. At least
one of these, IL4 )589C>T (rs2243250), seems a functional
polymorphism. The )589T allele (which is identical to the
variant)590T in ref. [3],)588T in ref. [9],)523T in ref. [14] and
)549T in ref. [12]) has been shown to increase IL-4 transcrip-
tional activity [3]. Detailed analysis of the sequence variations
in the structural IL-4 gene in 23 Caucasians revealed that the
)589T allele is part of a common haplotype [18]. In this
haplotype, the )589C>T is completely linked to 18 other
SNPs among which is the 33C>T SNP (rs2070874) in the 5¢
untranslated region (UTR) of exon 1. The )589C>T SNP is
the only variation in the promoter region of this IL4 haplotype.
Both the )589C>T and the 33C>T SNPs have been found to
influence intermediate phenotypes such as IL-4 production
[19,20] and IgE levels [4–6] as well as the severity and
Correspondence: Frits R. Rosendaal, Department of Clinical
Epidemiology, C9-P, Leiden University Medical Center,
Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
Tel.: +31 715264037; fax: +31 715266994.
E-mail: f.r.rosendaal@lumc.nl
Received 13 May 2008, accepted 17 July 2008
Journal of Thrombosis and Haemostasis, 6: 1633–1638 DOI: 10.1111/j.1538-7836.2008.03096.x
 2008 International Society on Thrombosis and Haemostasis
progression of a number of inflammatory and immune
disorders, for example asthma [7], multiple sclerosis [14,15]
and type 1 diabetes [21].
Recently, it was reported that the 582T allele (which is
identical to the )589T allele) increased the risk of stroke 1.5-
fold for heterozygotes and 1.7-fold for homozygotes [22],
indicating that functional variation in the IL-4 gene might
influence progression of atherosclerosis and onset of athero-
thrombosis. Therefore we investigated the association of the
)589T containing haplotypes of the IL-4 gene with the risk of
MI. The )589C>T SNP, as well as the 33C>T SNP which is
reported to be strongly linked to the )589C>T SNP, were
used to tag these haplotypes.
Methods
Study population SMILE (discovery study)
In the Study of Myocardial Infarction Leiden (SMILE), we
included 560 consecutive men who survived a first MI, which
had occurred between January 1990 and November 1994 as
patients, and 646 healthy men as control subjects. The median
(5th–95th percentile) age of patients was 58 (40–72) years and
in control subjects 59 (35–72) years. Control subjects had
undergone an orthopedic intervention between January 1990
and May 1996 and had received prophylactic anticoagulants
for only a short period after the intervention. They had not
used anticoagulants for at least 6 months prior to participation
in the study. The median time between orthopedic intervention
and participation in the study was 2.9 years.
Excluded were men with renal disease, severe (neuro)psy-
chiatric problems or a life expectancy less than 1 year. Details
of SMILE, including the diagnosis of MI patients, have been
described elsewhere [23].
Study population Valencia (replication study)
In the Valencia study [24] the patient group included 305
Caucasian MI survivors (261 men, 44 women) aged
£52 years [median age (5th–95th percentile) 45 (34–50) years;
men 45 (34–50) years, women 45 (30–51) years] at the time of
the acute event. Myocardial infarction was diagnosed as
previously reported [25]. Patients with malignancy, nephrotic
syndrome, renal or hepatic dysfunction, inflammatory or
infectious diseases or lupus anticoagulant were excluded. The
control group was recruited along with the cases and
comprised 310 unrelated Caucasian age- and sex-matched
volunteers (246 men, 64 women) with a median age of 44
(29–62) years [men 44 (28–64) years, women 44 (30–54)
years] from the same geographical area as the MI patients.
They were friends or partners of patients, or persons who
visited the hospital for medical checkups. All controls were
apparently healthy and none had a personal or family history
of thrombotic disease.
In both studies, all classic risk factors for MI, such as
smoking or metabolic risk factors (obesity, diabetes, hyper-
cholesterolemia and hypertension), were more frequently
present in patients than in control subjects [23,24].
Genetic analysis
Genotyping of the )589C/T SNP (rs2243250) in IL-4 was
performed using the 5¢ nuclease/TaqMan assay [26]. Polymer-
ase chain reaction (PCR) with fluorescent allele-specific oligo-
nucleotide probes (Applied Biosystems, Foster City, CA,USA)
was performed on a PTC-225 (Biozym, Hess. Oldendorf,
Germany) or TC-412 thermal cycler (Techne, Stone, Stafford-
shire, UK). Allelic discrimination was obtained by endpoint
measurement performed on an ABI 7000 or ABI 7900 HT
(Applied Biosystems). Primer sequences, probe sequences and
amplification conditions used are available on request. Geno-
typing succeeded in 559 patients and 645 control subjects of the
SMILE (99.8% of all samples) and in all subjects of the
Valencia study.
In the SMILE, the 33C>T SNP (rs2070874) was measured
using Homogeneous Mass Extension system technology con-
sisting of PCR, mini-sequencing and Matrix-Assisted Laser
Desorption Ionization Time-of-Flight technology (MALDI-
TOF; Sequenom, San Diego, CA, USA) [27]. Genotyping
succeeded in 1181 (98.0%) samples.
Fibrinogen, CRP and F1+2 measurements
C-reactive protein (CRP) was measured previously in SMILE
by EIA HS assay (Kordia, Leiden, the Netherlands) and in the
Valencia study using a high-sensitive nephelometric assay
(Behringwerke AG, Marburg, Germany). F1+2 levels were
measured in the Valencia study by commercial ELISA (Enzy-
gnost F1.2 micro; Dade-Behring, Marburg, Germany). Fibrin-
ogen levels were measured in SMILE using the Claus method.
Statistical analysis
Odds ratios (OR)with 95%confidence intervals (95%CI) were
calculated as measure of relative risk [28]. The index date for
patients was the date of their first MI and the index date for
control subjects was the date of inclusion in the study.
Comparison of CRP levels between genotypes was made after
logarithmic transformation of the data. Differences between
the log-transformed data were tested by means of analysis of
variance (ANOVA). All values presented were converted back to
geometric means with the appropriate 95% CIs.
Results
)589C>T and 33C>T genotypes
In Caucasians, )589T and 33T seem to tag the same IL-4
haplotype groups [18]. To confirm this we genotyped 1206
subjects of the SMILE for both polymorphisms. Both
polymorphisms were successfully genotyped in 1181 subjects.
Among them, concordant results were obtained in 1176
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patients (99.6%) with the following distribution: 881 subjects
were CC for both polymorphisms, 270 CT and 23 TT for both
polymorphisms. The five (0.4%) discordant results obtained
comprised three subjects homozygous for )589C and hetero-
zygous for 33C>T, and two subjects homozygous for 33C and
heterozygous for )589C>T. Genotypic distributions in con-
trols were in Hardy–Weinberg equilibrium (P = 0.77). The
frequency of haplotypes carrying both )589T and – 33T in the
control subjects was 0.14. For subsequent analyses we focused
on the )589C>T polymorphism.
)589C>T and risk of MI
We used the SMILE to discover possible associations
between )589C>T genotypes and the risk of MI. Table 1
shows the distribution of the )589C>T genotypes in patients
(n = 559) with a first MI and control subjects (n = 645).
Overall no clear association between the presence of the
)589T genotype and the risk of MI was found. The OR for
MI was around 0.82 for both heterozygous and homozygous
carriers of the )589T allele compared with )589CC carriers.
This small protective effect of the )589T allele was more
pronounced in individuals younger than 50 years at the index
date (OR 0.60; 95% CI 0.35–1.02 for heterozygous carriers
and 0.23; 95% CI 0.02–2.05 for homozygous carriers). Thus,
young carriers of one or two )589T alleles had a lower risk
of developing MI (OR 0.57: 95% CI 0.34–0.95). In men over
50 years, there was no clear effect of the )589T allele on risk
of MI (TT and CT carriers combined: OR 0.93; 95% CI
0.69–1.26). Smoking and the presence of metabolic risk
factors did not influence the effect of the )589T allele on the
risk of MI (Table 2).
To replicate our findings on the )589T allele in young men,
we genotyped the 615 participants of the Valencia study (305
patients and 310 controls) for the )589C>T polymorphism.
The Valencia study included only young individuals and both
men and women [24]. The genotypic distribution in the 310
control subjects was in Hardy–Weinberg Equilibrium
(P = 0.9). Table 3 shows a reduced risk of MI in carriers of
one or two )589T alleles not only in the overall group (OR
0.67; 95% CI 0.47–0.95), but also in a detailed sub-analysis by
gender (Table 4).
)589C>T and CRP levels
In control subjects of SMILE, the )589T allele did not appear
to affect plasma levels of CRP (geometric mean CRP in
)589TT carriers of 2.58 mg L)1, 95%CI 1.42–4.68, in)589CT
carriers of 1.52, 95% CI 1.27–1.82, and in )589CC carriers
1.76 mg L)1 CRP, 95% CI 1.58–1.97) (ANOVA P > 0.10).
Similar data were obtained in the healthy subjects of the
Valencia study (geometric mean CRP in )589TT carriers of
1.13 mg L)1, 95% CI 0.74–1.75, in )589CT carriers
1.01 mg L)1, 95% CI 0.89–1.14, and in )589CC carriers
1.13 mg L)1, 95% CI 1.04–1.24) (ANOVA P > 0.10).
)589C>T and F1+2 levels
In the control subjects of the Valencia study, the )589T allele
was associated with reduced plasma levels of F1+2 (see
Table 1 Distribution of the genotype of the IL-4 )589C>T polymor-
phism in patients with myocardial infarction (MI) and control subjects of
the Study of Myocardial Infarctions Leiden (SMILE) overall and in men
<50 years (discovery study)
)589C>T
genotype
Cases (%)
n = 559
Controls (%)
n = 645
OR
(95% CI)
Overall
CC 430 (77) 472 (73) 1*
CT 119 (21) 160 (25) 0.82 (0.62–1.07)
TT 10 (2) 13 (2) 0.84 (0.37–1.95)
TT & CT 129 (23) 173 (27) 0.82 (0.63–1.06)
n = 154 n = 160
<50 years
CC 124 (80) 112 (70) 1*
CT 29 (19) 44 (27) 0.60 (0.35–1.02)
TT 1 (1) 4 (3) 0.23 (0.02–2.05)
TT & CT 30 (20) 48 (30) 0.57 (0.34–0.95)
Odds ratio (OR) and 95% confidence interval (CI). *Reference cate-
gory.
Table 2 The effect of smoking and the presence of metabolic risk factors
combined with the IL-4 )589C>T genotype on the risk of myocardial
infarction (MI) in Study of Myocardial Infarctions Leiden (SMILE)
(discovery study)
Genotype Smoking
Cases (%)
n = 559
Controls (%)
n = 645
OR
(95% CI)
CC No 162 (29) 311 (48) 1*
CC Yes 268 (48) 161 (25) 3.20 (2.43–4.20)
TT & CT No 49 (9) 120 (19) 0.78 (0.54–1.15)
TT & CT Yes 80 (14) 53 (8) 2.90 (1.95–4.30)
Metabolic
risk factors
CC No 272 (49) 321 (50) 1*
CC Yes 158 (28) 151 (23) 1.23 (0.94–1.63)
TT & CT No 83 (15) 127 (20) 0.77 (0.56–1.06)
TT & CT Yes 46 (8) 46 (7) 1.18 (0.76–1.83)
Odds ratio (OR) and 95% confidence interval (CI). *Reference cate-
gory.
Table 3 Distribution of IL-4 )589C>T genotypes in patients with
myocardial infarction (MI) and control subjects of the Valencia study
(replication study)
)589C>T
genotype
Cases (%)
n = 305
Controls (%)
n = 310
OR (95% CI)
Overall
CC 228 (75) 206 (67) 1*
CT 73 (24) 93 (30) 0.71 (0.50–1.02)
TT 4 (1) 11 (3) 0.33 (0.10–1.05)
TT & CT 77 (25) 104 (33) 0.67 (0.47–0.95)
Odds ratio (OR) and 95% confidence interval (CI). *Reference cate-
gory.
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Table 5). In carriers of the )589T allele, F1+2 levels were
0.785 nM (95%CI 0.851–0.916) comparedwith 0.883 nM (95%
CI 0.743–0.827) in non-carriers (P-value ANOVA <0.001).
)589C>T and fibrinogen levels
In the control subjects of SMILE, the )589T allele was not
associated with fibrinogen levels. In carriers of the)589T allele,
fibrinogen was 3.21 g L)1 (95% CI 3.11–3.30) compared with
3.27 g L)1 (95% CI 3.21–3.33) (P-value ANOVA >0.10).
Discussion
Our data indicate that the IL-4 haplotypes tagged by the)589T
allele reduce the risk of premature MI. Because atherosclerosis
is classically considered to be a Th1-mediated disease, the
observed protective effect of the )589T allele would be in
accordance with the delayed progression of other Th1-type
diseases such as rheumatoid arthritis and multiple sclerosis in
carriers of the )589T allele or 33T allele [12–14,17]. Interest-
ingly, the same haplotypes seem to enhance the severity of the
disease in Th2-type diseases such as severe asthma and IgA
nephropathy [4,7], and were recently found to enhance the risk
of stroke in a nested case–control study (OR 1.40; 95% CI
1.13–1.73) [22]. The latter observation, if confirmed, would
indicate important differences in the pathophysiology of acute
stroke and acute MI. In our studies, CRP and fibrinogen levels
appeared not to be influenced by the )589C>T polymor-
phism, while F1+2 levels were found to be reduced in )589T
carriers.
In case of MI, the )589T allele of IL-4, which is associated
with increased IL-4 expression [3,19,20], may influence both the
inflammatory process underlying the progression of athero-
sclerosis and the thrombotic event itself. For instance, IL-4 has
been reported to inhibit the expression of fibrinogen by
stimulated hepatocytes [29] and the expression of tissue factor
by stimulated monocytes [30–32]. The pronounced effect of IL-
4 on inflammation is most probably the cause of diminished
monocyte recruitment and activity, weakened Th1 functioning
and delayed progression of vascular injury, which overall might
result in delayed progression of atherosclerosis and develop-
ment of atherothrombosis. However, this view is not supported
by observations in IL-4-deficient mice in which the absence of
IL-4 resulted in reduced atherogenesis [33,34,35]. Also, data
have been presented that indicate that IL-4 can induce a pro-
inflammatory environment via oxidative stress-mediated up-
regulation of inflammatory mediators [36] and that blocking of
the OX40/OX40L interaction reduces atherogenesis by inhibi-
tion of IL-4-mediated Th2-induced isotype switching [37].
These apparently conflicting datamake it difficult to predict the
effect on atherogenesis of lifelong exposure to enhanced IL-4
expression, as is the case in carriers of the IL4 )589T allele. The
finding that plasma CRP levels, which are widely recognized as
the best inflammatory marker, were not associated with the IL-
4 haplotype may suggest that the most important mechanism
by which the IL-4 )589T allele exerts a protective effect for
early MI might be the down-regulation of the coagulation
cascade. The latter hypothesis is supported by our finding of
reduced F1+2 levels in carriers of the )589T allele.
The )589T and 33T variations in IL-4 also occur in non-
Caucasian populations with frequencies up to 0.7. Rockman
et al. argued that this large variation in allele frequency
between different populations might represent local adaptation
to diverse pathological challenges [38]. In the control subjects of
SMILE, we found a frequency of 0.14 for both the)589T allele
and the 33T allele. In the control subjects of the Valencia study
the frequency of the )589T allele is slightly higher (0.18). These
frequencies are very similar to those reported in other studies of
Caucasian populations, but are much lower than those
reported for subjects of African descent [5,18]. Previous studies
showed that in Caucasians the )589T and 33T tag one unique
haplotype [18], whereas these two variations were not com-
pletely linked and present in several haplotypes in subjects from
African descent [13,18]. There is a large difference between
different ethnic groups in the haplotypes tagged by the
)589C>T and 33C>T polymorphisms. These differences in
haplotype structure and frequencies between different ethnic
groupsmay have contributed to the variable results obtained in
some of the disease association studies.
So far, there is one study which documents the functionality
of the )589C>T polymorphism [3]. Given the large number of
SNPs linked to this polymorphism [18] and the complexity of
the haplotype structure of IL-4 in different ethnic groups, it will
Table 4 IL-4 )589C>T genotypes and the risk of myocardial infarction
(MI) among men and women in the Valencia study (replication study)
IL-4 )589C>T
genotype
Cases (%)
n = 261
Controls (%)
n = 246 OR (95% CI)
In men
CC 194 (74) 166 (67) 1*
CT 64 (25) 69 (28.0) 0.79 (0.53–1.18)
TT 3 (1) 11 (4) 0.23 (0.03–2.05)
TT & CT 67 (26) 80 (32) 0.72 (0.06–0.85)
n = 44 n = 64
In women
CC 34 (77) 40 (62) 1*
CT 9 (21) 24 (38) 0.44 (0.18–1.08)
TT 1 (2) 0 (0) –
TT & CT 10 (23) 24 (38) 0.49 (0.21–1.17)
Odds ratio (OR) and 95% confidence interval (CI). *Reference cate-
gory.
Table 5 Effect of IL-4 )589C>T genotypes on F1+2 levels in control
subjects of the Valencia study
IL4 )589C>T
genotype
Control subjects
(n = 282)*
F1 + 2 (nM)
Mean (95% CI)
CC 188 0.883 (0.851–0.916)
CT 84 0.793 (0.748–0.839)
TT 10 0.717 (0.597–0.873)
P-value ANOVA <0.01. *F1+2 missing in 28 control subjects.
1636 E. Paffen et al
 2008 International Society on Thrombosis and Haemostasis
be useful to confirm these findings and to investigate the
presence of other functional polymorphisms in the haplotype
tagged by the )589T and 33T allele.
In the present study, we demonstrated that a genetic
variation in IL-4 might provide protection against the
premature onset of MI. This was most evident in the young,
where the effect of the genetic variation may be stronger as a
result of the relative absence of age-related risk factors.
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